Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Upadacitinib in Axial Spondyloarthritis
NCT07770646Phase 4Not yet recruiting
- Sponsor
- UTHealth Houston
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab, upadacitinib in axial spondyloarthritis (axSpA), sponsored by UTHealth Houston. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
secukinumabupadacitinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT07770646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770646.